Factor VII (coagulation factor VII) is a 50 kD multidomain single chain plasma glycoprotein synthesized in the liver. It is a vitamin K-dependent serine protease essential for the extrinsic pathway of hemostasis, or blood coagulation. Factor VII circulates in the blood in a zymogen form that is converted to an active form (via factor IXa, factor Xa, factor XIIa, or thrombin). Rare bleeding disorders (RBDs) are rare within the general community, but present both a diagnostic and effective treatment challenge due to the highly variable range in clinical presentation and cause. Defects in Factor VII cause coagulopathy and hemorrhagic disease, which range in severity from mild tolerable events to acutely severe and repeated hemarthroses and life-threatening intracerebral hemorrhages.
Immunohistochemistry-Paraffin: Factor VII Antibody
A review by James attempts to validate an adequate bleeding assessment tool, laboratory aspects, phenotyping, and optimal management of RBDs1. Recent work using the Factor VII antibody from Favaloro’s group describes laboratory markers for hemostasis with regards to aging and age-related changes2. His review addresses changes in current measurable markers (Factors V, VII, and VIII, fibrinogen) and their implication for clinical and laboratory practice. Interesting work out of Unlu’s lab in the Netherlands used some Factor VII antibody experiments to correlate links between tumor-expressed coagulation factors and cancer progression and venous thrombosis3. Their publication reviews molecules such as tissue factor (TF), ectopic thrombin, and Factors VII and X on tumor growth and angiogenesis.
Novus Biologicals offers Factor VII reagents for your research needs including:
PMIDs
